H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with
placebo in a 12-week trial that includes Medical Management. This study is an outpatient
study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will
be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for
twelve weeks.